


WHAT IS CLAIMED IS:

1. A compound of the formula I:



I

wherein:

W is selected from the group consisting of:

- (1) tetrazolyl,
- (2) CO₂H,
- (3) NHSO₂C₁₋₆alkyl, and
- (4) CONHCO-C₁₋₆alkyl;

X is selected from the group consisting of:

- (1) -O-,
- (2) -S-, and
- (3) -NH-,
- (4) -N(C₁₋₆alkyl)-,
- (5) a bond;

Y is selected from the group consisting of:

- (1) -O-, and
- (2) -S-;

R₁ is selected from the group consisting of:

- (1) C₁₋₆alkyl, which is unsubstituted or substituted with a substituent selected from:
 - (a) halogen,
 - (b) hydroxyl, and
 - (c) phenyl, wherein the phenyl is unsubstituted or substituted with 1-5 substituents independently selected from halogen, cyano, CF₃, hydroxyl, C₁₋₆alkyl, and OC₁₋₆alkyl,

- (2) C₃₋₇cycloalkyl, which is unsubstituted or substituted with halogen, hydroxyl or phenyl, and
- (3) phenyl, wherein the phenyl is unsubstituted or substituted with 1-5 substituents independently selected from halogen, hydroxyl, cyano, CF₃, C₁₋₆alkyl, and OC₁₋₆alkyl, wherein the C₁₋₆alkyl and OC₁₋₆alkyl are linear or branched and optionally substituted with 1-5 halogen;

R₂ is selected from the group consisting of:

- (1) hydroxyl,
- (2) halogen,
- (3) OC₁₋₆alkyl, and
- (4) C₁₋₆alkyl, which is unsubstituted or substituted with halogen, hydroxyl or phenyl;

R₃ is selected from the group consisting of:

- (1) C₁₋₆alkyl, which is unsubstituted or substituted with halogen, hydroxyl or phenyl, and
- (2) halogen, and
- (3) hydrogen;

R₄ is selected from the group consisting of:

- (1) hydrogen,
- (2) halogen, and
- (3) C₁₋₆alkyl;

m is an integer selected from 0, 1, 2 and 3;

n is an integer selected from 0, 1, 2, 3, 4, 5 and 6;

and pharmaceutically acceptable salts thereof and individual diastereomers thereof.

2. The compound of Claim 1 wherein W is selected from tetrazolyl and

3. The compound of Claim 1 wherein X is -O-.

4. The compound of Claim 1 wherein Y is -O-.

5. The compound of Claim 1 wherein X is a bond and Y is -O-.

6. The compound of Claim 1 wherein R¹ is selected from

- 5 (1) C₁-6alkyl, and
(2) C₅-6cycloalkyl.

7. The compound of Claim 6 wherein R¹ is selected from

- 10 (1) CH₃,
(2) CH(CH₃)₂,
(3) CH₂CH₃,
(4) CH₂CH₂CH₃,
(5) cyclopentyl,
(6) CH₂-cyclopentyl,
15 (7) phenyl, and
(8) CH₂phenyl.

8. The compound of Claim 1 wherein R² is selected from hydroxyl and

chloro.

20 9. The compound of Claim 1 wherein R³ is selected from

- (1) C₁-6alkyl,
(2) CH₃,
(3) CH₂CH₃,
25 (4) CH₂CH₂CH₃, and
(5) chloro.






10. The compound of Claim 1 wherein R⁴ is hydrogen.






11. The compound of Claim 1 wherein m is 0 or 1.






12. The compound of Claim 1 wherein n is selected from






1, 2, 3 or 4.






13. A compound which is selected from the group consisting of:































and pharmaceutically acceptable salts thereof.

14. A pharmaceutical composition which comprises an inert carrier and a compound of Claim 1.

15. A method for potentiation of metabotropic glutamate receptor activity in a mammal which comprises the administration of an effective amount of the compound of Claim 1.

16. A method for the manufacture of a medicament for potentiation of metabotropic glutamate receptor activity in a mammal comprising combining the compound of Claim 1 with a pharmaceutical carrier or diluent.

5 17. A method for treating a neurological and psychiatric disorders associated with glutamate dysfunction in a mammalian patient in need of such which comprises administering to the patient a therapeutically effective amount of a compound of Claim 1.

10 18. A method for treating anxiety in a mammalian patient in need of such which comprises administering to the patient a therapeutically effective amount of a compound of Claim 1.

15 19. A method for treating depression in a mammalian patient in need of such which comprises administering to the patient a therapeutically effective amount of a compound of Claim 1.

20 20. A method for treating migraine in a mammalian patient in need of such which comprises administering to the patient a therapeutically effective amount of a compound of Claim 1.

21. A method for treating schizophrenia in a mammalian patient in need of such which comprises administering to the patient a therapeutically effective amount of a compound of Claim 1.

25 22. A method for treating epilepsy in a mammalian patient in need of such which comprises administering to the patient a therapeutically effective amount of a compound of Claim 1.